SHR-1316 Injection
Sponsors
Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd
Conditions
Advanced Cervical CancerAdvanced Solid TumorsMalignant Solid TumorMalignant Solid TumorsPD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast CancerSolid TumorWidespread Small Cell Lung Cancer
Phase 1
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
RecruitingNCT06474455
Start: 2024-07-02End: 2029-12-01Target: 156Updated: 2026-05-11
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Active, not recruitingNCT07009457
Start: 2025-06-16End: 2028-09-01Updated: 2026-06-30
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
RecruitingNCT07136142
Start: 2025-09-23End: 2027-02-01Target: 150Updated: 2026-09-23
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
RecruitingNCT07229586
Start: 2025-12-02End: 2027-12-31Target: 100Updated: 2025-12-19
Phase 2
Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
RecruitingNCT07111832
Start: 2025-08-20End: 2028-12-31Target: 400Updated: 2025-12-18
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
RecruitingNCT07168200
Start: 2025-10-17End: 2028-12-01Target: 720Updated: 2026-04-15